The following section is provided to help you better evaluate the efficacy, safety, and benefits of ZUPLENZ® (ondansetron). For further details about ZUPLENZ, please see the complete Prescribing Information.




  What are the indications for ZUPLENZ?

ZUPLENZ is indicated for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

  What is the active ingredient in ZUPLENZ?

The active ingredient in ZUPLENZ is ondansetron, which has been shown to be effective in the prevention
of nausea and vomiting. ZUPLENZ is available in 4-mg and 8-mg doses.

  How is ZUPLENZ different from other antiemetics?

ZUPLENZ is the first and only 5-HT3 antagonist available in an oral soluble film that prevents nausea and vomiting. ZUPLENZ films dissolve rapidly in the mouth in about 10 seconds and can be taken with or without water. Each peppermint-flavored film is individually packaged for discreet, on-the-go use.

  How does ZUPLENZ compare to ondansetron orally disintegrating tablets?

In 3 clinical studies, under varying conditions, ZUPLENZ was found to be comparable to ondansetron orally disintegrating tablets.

ZUPLENZ delivers the trusted efficacy of ondansetron in a quick-dissolving film. ZUPLENZ dissolves rapidly in the mouth in about 10 seconds and can be taken with or without water.

  What is the recommended dosing for ZUPLENZ?

ZUPLENZ is available in 4-mg and 8-mg films, the same strength of oral ondansetron, with the same recommended dosing. Dosing varies according to indication. Please refer to the complete Prescribing Information for ZUPLENZ.

  What are the most common side effects of ZUPLENZ?

The most common side effects of ZUPLENZ are headache, tiredness and body discomfort, constipation, and diarrhea.


For the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

The concomitant use of apomorphine with ondansetron is contraindicated based upon reports of profound hypotension and loss of consciousness.

Patients known to have hypersensitivity to ondansetron and to other selective 5-HT3 receptor antagonists should not take ZUPLENZ. Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported. Rarely and predominantly with intravenous ondansetron, transient electrocardiographic changes, including QT interval prolongation, have occurred.

The use of ZUPLENZ in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension. ZUPLENZ does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction.

The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron for prevention of nausea and vomiting associated with cancer chemotherapy or radiotherapy were headache, malaise/fatigue, constipation, and diarrhea. For postoperative nausea and vomiting, headache occurred at a rate significantly different from placebo.

ZUPLENZ is available by prescription only. Please click here for complete Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

For more information about ZUPLENZ, call 1-888-834-7800.